GlassScriptPhysician profile
Nasir S Syed
NPI 1659373868
$2,982.17
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,294 · 2020: $688.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $846.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.19 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $371.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $324.48 | 2019 | |
| Glaxosmithkline, LLC. | $193.99 | 2019-2020 | |
| Grifols USA, LLC | $184.74 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $128.66 | 2019 | |
| Genzyme Corporation | $109.25 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $75.02 | 2019-2020 | |
| Resmed Corp | $46.05 | 2019 | |
| United Therapeutics Corporation | $44.19 | 2019 | |
| Philips North America LLC | $37.91 | 2019 | |
| Stimwave Technologies Incorporated | $35.28 | 2019 | |
| Mylan Specialty L.P. | $27.70 | 2019-2020 | |
| Gilead Sciences, INC. | $21.64 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2020 | |
| Shire North American Group INC | $14.37 | 2019 | |
| Antares Pharma, INC. | $14.07 | 2019 | |
| Genentech USA, INC. | $13.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasir Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.